Here are the 10-Q quarterly reports from Lakewood-Amedex Biotherapeutics Inc. (LABT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LABT filings page.
Lakewood-Amedex Biotherapeutics Inc. reported a larger net loss of $4.7 million for the six months ended June 30, 2026, up from $1.2 million a year earlier, driven mainly by higher general and administrative costs associated with becoming a Nasdaq-listed company and ramping clinical activity.
Cash and cash equivalents rose to $2.6 million, with an additional $2.0 million in certificates of deposit, compared with $0.2 million in cash at year-end 2025. The improvement reflects a private placement of 937,500 Series C Convertible Preferred shares, providing $7.5 million in gross and about $6.8 million in net proceeds and converting prior preferred stock and convertible notes into common stock.
Despite the stronger balance sheet and working capital of about $4.2 million, management states that recurring losses and expected cash use raise substantial doubt about the company’s ability to continue as a going concern beyond early 2027 without additional financing. Management also concludes that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
Lakewood-Amedex Biotherapeutics Inc. reported a net loss of $923,291 for the quarter ended March 31, 2026, with no revenue and an accumulated deficit of $54.3 million. Operating expenses rose to $886,750, driven mainly by higher general and administrative costs linked to Nasdaq listing preparation.
Cash and cash equivalents were $11,709 at quarter-end against total liabilities of $3.0 million and a stockholders’ deficit of $2.8 million, leading management to state that substantial doubt exists about the company’s ability to continue as a going concern. After quarter-end, the company completed a $7.5 million Series C Convertible Preferred Stock financing, receiving approximately $6.8 million net, and all Series A and B preferred shares and $1.5 million of convertible notes converted into common stock upon its Nasdaq Capital Market listing. Management believes this funding supports operations through the fourth quarter of 2026 but still anticipates needing additional capital.